The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
Open accessAbstract
Purpose: Hepatocellular carcinoma (HCC) incidence rates have been increasing in the United States for the past 35 years. Because HCC has a poor prognosis, quantitative forecasts could help to inform prevention and treatment strategies to reduce the incidence and burden of HCC. Methods: Single-year HCC incident case and population data for the years 2000 to 2012 and ages 35 to 84 years were obtained from the SEER 18 Registry Database. We forecast incident HCC cases through 2030, using novel age-period-cohort models and stratifying by sex, race/ethnicity, and age. Rates are presented because absolute numbers may be influenced by population increases. Results: Rates of HCC increased with each successive birth cohort through 1959. However, rates began to decrease with the 1960 to 1969 birth cohorts. Asians/Pacific Islanders (APIs) have had the highest HCC rates in the United States for many years, but the rates have stabilized and begun to decline in recent years. Between 2013 and 2030, rates among APIs are forecast to decline further, with estimated annual percentage changes of −1.59% among men and −2.20% among women. Thus, by 2030, Asians are forecast to have the lowest incidence rates among men, and Hispanics are forecast to have the highest rates among men (age-standardized rate, 44.2). Blacks are forecast to have the highest rate among women (age-standardized rate, 12.82). Conclusion: Although liver cancer has long had some of the most rapidly increasing incidence rates, the decreasing rates seen among APIs, individuals younger than 65 years, and cohorts born after 1960 suggest that there will be declines in incidence of HCC in future years. Prevention efforts should be focused on individuals in the 1950 to 1959 birth cohorts, Hispanics, and blacks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Permutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,805
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N., & Buchholz, T. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8983 · Cited by 1,721
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Self-citationObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y. T., Holtzman, D. J., Teo, C., Jewett, A., Baack, B. N., Rein, D. B., Patel, N., et al. (2012) · PubMed · Cited by 991
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Global Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.01.001 · Cited by 908
Self-citationKim, H. (2001) · Statistics in Medicine · doi:10.1002/sim.811 · Cited by 873
A Web Tool for Age–Period–Cohort Analysis of Cancer Incidence and Mortality Rates
Rosenberg, P. S., Check, D. P., & Anderson, W. F. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0300 · Cited by 819
Self-citationCancers with increasing incidence trends in the United States: 1999 through 2008
Simard, E. P., Ward, E. M., Siegel, R., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20141 · Cited by 724
Prevalence of obesity among adults: United States, 2011-2012.
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2013) · PubMed · Cited by 502
Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States
Altekruse, S. F., Henley, J. S., Cucinelli, J. E., & McGlynn, K. A. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.11 · Cited by 429
Self-citationChhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States
Welzel, T. M., Graubard, B. I., Quraishi, S., Zeuzem, S., Davila, J. A., El-Serag, H. B., & McGlynn, K. A. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.160 · Cited by 328
Self-citationImpact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends
Clegg, L. X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1537 · Cited by 278
The past, present, and future of cancer incidence in the United States: 1975 through 2020
Weir, H. K., Thompson, T. D., Soman, A., Møller, B., & Leadbetter, S. (2015) · Cancer · doi:10.1002/cncr.29258 · Cited by 276
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients
Greten, T. F., Papendorf, F., Bleck, J. S., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., Galanski, M., & Manns, M. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602590 · Cited by 194
The Status of Baby Boomers' Health in the United States
King, D. E., Matheson, E. M., Chirina, S., Shankar, A., & Broman-Fulks, J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2006 · Cited by 150
Rosenberg, P. S., Barker, K. A., & Anderson, W. F. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv159 · Cited by 142
Self-citationHistological classification of liver and intrahepatic bile duct cancers in SEER registries.
Altekruse, S. F., Devesa, S. S., Dickie, L. A., McGlynn, K. A., & Kleiner, D. E. (2011) · PubMed · Cited by 141
Self-citationCancer in first and second generation Americans.
Thomas, D. B., & Karagas, M. R. (1987) · PubMed · Cited by 114
Earlier presentation and application of curative treatments in hepatocellular carcinoma
Ulahannan, S. V., Duffy, A. G., McNeel, T. S., Kish, J. K., Dickie, L. A., Rahma, O. E., McGlynn, K. A., Greten, T. F., & Altekruse, S. F. (2014) · Hepatology · doi:10.1002/hep.27288 · Cited by 83
Self-citationAltekruse, S. F., Petrick, J. L., Rolin, A. I., Cucinelli, J. E., Zou, Z., Tatalovich, Z., & McGlynn, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120574 · Cited by 79
Self-citationHowlader, N., Ries, L. A. G., Stinchcomb, D. G., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn517 · Cited by 75
Cancer‐related risk factors and preventive measures in US Hispanics/Latinos
Cokkinides, V. E., Bandi, P., Siegel, R. L., & Jemal, A. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21155 · Cited by 60
HCV Treatment — No More Room for Interferonologists?
Drenth, J. P. H. (2013) · New England Journal of Medicine · doi:10.1056/nejme1303818 · Cited by 37
Heuristic Algorithms for Assigning Hispanic Ethnicity
Boscoe, F. P., Schymura, M. J., Zhang, X., & KRAMER, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055689 · Cited by 22
Cited by
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Self-citationHepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,048
Metadata
- Authors
- Petrick, J. L., Kelly, S. P., Altekruse, S. F., McGlynn, K. A., & Rosenberg, P. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-20
- Volume
- 34
- Issue
- 15
- Pages
- 1787-1794
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2341369626
- Cited by
- 442
- References
- 33
- FWCI
- 24.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.